Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Beatriz Grandal, Clémence Evrevin, View ORCID ProfileEnora Laas, Isabelle Jardin, Sonia Rozette, View ORCID ProfileLucie Laot, View ORCID ProfileElise Dumas, View ORCID ProfileFlorence Coussy, View ORCID ProfileJean-Yves Pierga, View ORCID ProfileEtienne Brain, View ORCID ProfileClaire Saule, View ORCID ProfileDominique Stoppa-Lyonnet, View ORCID ProfileSophie Frank, Claire Sénéchal, Marick Lae, Diane De Croze, View ORCID ProfileGuillaume Bataillon, Julien Guerin, View ORCID ProfileFabien Reyal, View ORCID ProfileAnne-Sophie Hamy
doi: https://doi.org/10.1101/2020.09.27.20202515
Beatriz Grandal
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
10Residual Tumor & Response to Treatment Laboratory, RT2Lab, translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d’Ulm, Paris, France
Clémence Evrevin
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Enora Laas
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Isabelle Jardin
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Sonia Rozette
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Lucie Laot
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Elise Dumas
10Residual Tumor & Response to Treatment Laboratory, RT2Lab, translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d’Ulm, Paris, France
Florence Coussy
2Department of Oncology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Jean-Yves Pierga
2Department of Oncology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Etienne Brain
3Department of Oncology, Centre René Huguenin – Institut Curie, 35 rue Dailly, 92210 St Cloud, France
Claire Saule
4Department of Genetics, Institut Curie, 26 rue d’Ulm, 75005 Paris, France INSERM U830, Institut Curie Paris, Paris, France
Dominique Stoppa-Lyonnet
4Department of Genetics, Institut Curie, 26 rue d’Ulm, 75005 Paris, France INSERM U830, Institut Curie Paris, Paris, France
Sophie Frank
4Department of Genetics, Institut Curie, 26 rue d’Ulm, 75005 Paris, France INSERM U830, Institut Curie Paris, Paris, France
Claire Sénéchal
5Department of Genetics, Institut Bergonié, 229 Cours de l’Argonne, 33000 Bordeaux, France
Marick Lae
6Department of Pathology, Centre René Huguenin - Institut Curie, 35 rue Dailly, 92210 St Cloud, France
7Department of Pathology, Centre Henri Becquerel, INSERM U1245, uniRouen, University of Normandie, Rouen, France
Diane De Croze
6Department of Pathology, Centre René Huguenin - Institut Curie, 35 rue Dailly, 92210 St Cloud, France
Guillaume Bataillon
8Department of Pathology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Julien Guerin
9Data Office, Institut Curie, 25 rue d’Ulm, 75005 Paris, France
Fabien Reyal
1Department of Surgery, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
10Residual Tumor & Response to Treatment Laboratory, RT2Lab, translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d’Ulm, Paris, France
Anne-Sophie Hamy
10Residual Tumor & Response to Treatment Laboratory, RT2Lab, translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d’Ulm, Paris, France
Article usage
Posted September 28, 2020.
Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Beatriz Grandal, Clémence Evrevin, Enora Laas, Isabelle Jardin, Sonia Rozette, Lucie Laot, Elise Dumas, Florence Coussy, Jean-Yves Pierga, Etienne Brain, Claire Saule, Dominique Stoppa-Lyonnet, Sophie Frank, Claire Sénéchal, Marick Lae, Diane De Croze, Guillaume Bataillon, Julien Guerin, Fabien Reyal, Anne-Sophie Hamy
medRxiv 2020.09.27.20202515; doi: https://doi.org/10.1101/2020.09.27.20202515
Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Beatriz Grandal, Clémence Evrevin, Enora Laas, Isabelle Jardin, Sonia Rozette, Lucie Laot, Elise Dumas, Florence Coussy, Jean-Yves Pierga, Etienne Brain, Claire Saule, Dominique Stoppa-Lyonnet, Sophie Frank, Claire Sénéchal, Marick Lae, Diane De Croze, Guillaume Bataillon, Julien Guerin, Fabien Reyal, Anne-Sophie Hamy
medRxiv 2020.09.27.20202515; doi: https://doi.org/10.1101/2020.09.27.20202515
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (709)
- Anesthesia (201)
- Cardiovascular Medicine (2944)
- Dermatology (249)
- Emergency Medicine (440)
- Epidemiology (12744)
- Forensic Medicine (12)
- Gastroenterology (828)
- Genetic and Genomic Medicine (4583)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2917)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (924)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4354)
- Nursing (236)
- Nutrition (639)
- Oncology (2268)
- Ophthalmology (646)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1196)
- Primary Care Research (496)
- Public and Global Health (6938)
- Radiology and Imaging (1527)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)